Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed at $1.4 up 14.75% from its previous closing price of $1.22. In other words, the price has increased by $14.75 from its previous closing price. On the day, 1.9 million shares were traded. CTXR stock price reached its highest trading level at $1.5399 during the session, while it also had its lowest trading level at $1.28.
Ratios:
For a deeper understanding of Citius Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.14 and its Current Ratio is at 0.47. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 25861068 and an Enterprise Value of 22111972.
Stock Price History:
The Beta on a monthly basis for CTXR is 1.54, which has changed by -0.57831323 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, CTXR has reached a high of $5.95, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 6.40%, while the 200-Day Moving Average is calculated to be 8.25%.
Shares Statistics:
For the past three months, CTXR has traded an average of 773.66K shares per day and 727360 over the past ten days. A total of 18.47M shares are outstanding, with a floating share count of 17.98M. Insiders hold about 2.67% of the company’s shares, while institutions hold 11.28% stake in the company. Shares short for CTXR as of 1763078400 were 2339794 with a Short Ratio of 3.02, compared to 1760486400 on 1581959. Therefore, it implies a Short% of Shares Outstanding of 2339794 and a Short% of Float of 13.01.
Earnings Estimates
. The current market rating for Citius Pharmaceuticals Inc (CTXR) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.3 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$2.08 and -$2.08 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is $1.9, with 1.0 analysts recommending between $1.9 and $1.9.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $3.46M. There is a high estimate of $3.46M for the next quarter, whereas the lowest estimate is $3.46M. Based on 2 analysts’ estimates, the company’s revenue will be $63.82M in the next fiscal year. The high estimate is $78.29M and the low estimate is $49.35M.
